Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

Exercise 25Metformin 23Tirzepatide 9Resistance Training 8Nutrition Assessment 8Methods 8Diet Therapy 8Diet 8Counseling 8Surveys and Questionnaires 6Early Intervention, Educational 6Caloric Restriction 6semaglutide 5Liraglutide 5Exenatide 5Diet, Mediterranean 5Blood Specimen Collection 5Educational Status 4Docosahexaenoic Acids 4Bariatric Surgery 4exemestane 3Vitamin D 3Therapeutics 3Tamoxifen 3Sugars 3Standard of Care 3Observation 3Naltrexone 3Letrozole 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Obesity × Medroxyprogesterone Acetate × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡